eGenesis Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

While start-up company financings increased from nearly $2.2bn in the third quarter to $3bn in the fourth quarter, mergers and acquisitions involving young biopharmaceutical companies declined from a

AN2 Launches With $12m In Series A Funding AN2 Therapeutics Inc. launched with $12m in series A financing led by Mountain Group Partners, which was joined by Adjuvant Capital, partner Brii Bioscien

Pfizer Inc. 's commitment of an additional $600m to its corporate venture capital fund includes a plan to spend 25% on neuroscience investments – a curious move considering the company's decision at t